This article summarized the latest R&D progress of Triclabendazole, the Mechanism of Action for Triclabendazole, and the drug target R&D trends for Triclabendazole.

In biology, a mutation is a permanent alteration to the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA.

Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.

This article summarized the latest R&D progress of Prazepam, the Mechanism of Action for Prazepam, and the drug target R&D trends for Prazepam.

The 2023 ESMO Congress marked a pivotal moment with the disclosure of a clinical trial for Osimertinib mesylate in EGFR-mutated NSCLC patients, opening avenues for further increases in its clinical efficacy.

Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.

The overexpression of the anti-apoptotic factor Myeloid Cell Leukemia 1 (MCL-1), caused by the activation of CDK9, will lead to the transformation of malignant tumor cells. Therefore, inhibiting CDK9 will downregulate MCL-1, thereby suppressing tumor growth.

This article summarized the latest R&D progress of Raloxifene Hydrochloride, the Mechanism of Action for Raloxifene Hydrochloride, and the drug target R&D trends for Raloxifene Hydrochloride.

The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.

A ketoreductase enzyme has undergone a gene mutation at a certain mutation site and has acquired a mutant enzyme with higher activity. How can one search for publicly available sequences of such enzyme mutants, as well as other popular mutation sites?

Small-molecule CDK2 selective inhibitors would be significant chemical probes for dissecting cellular processes or understanding the basics of diseases.

This article summarized the latest R&D progress of Reslizumab, the Mechanism of Action for Reslizumab, and the drug target R&D trends for Reslizumab.